IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $95.73M rose 35.0% year over year, ahead of the +5.2% change in trailing-twelve-month research & development. Sequentially, it rose 10.5% from the prior quarter. Over 3 fiscal years it compounded at +52.0% a year.
Context
- Research & development amounted to 143.9% of revenue in FY2025, down 4065.7 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +35.0% holds above the trailing-twelve-month pace of +5.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 314.7M USD
- Year-over-year change
- +6.8%
- 4-year CAGR
- +52.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 314.7M | +6.8% |
| FY2024 | 2024-12-31 | 294.67M | +127.5% |
| FY2023 | 2023-12-31 | 129.51M | +44.6% |
| FY2022 | 2022-12-31 | 89.54M | +54.0% |
| FY2021 | 2021-12-31 | 58.16M | — |
Research & Development vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 research & development of $339.54M is the 2nd highest of the 9 companies compared; the peer median is $143.04M.
- Its year-over-year change of +5.2% is the 7th highest of 9, against a peer median of +15.1%.
- Research & development amounts to 150.7% of revenue for IDYA, versus a peer median of 270.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.29B | +68.1% | +57.0% | — | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Jun 2026 | $289.55M | +15.9% | +30.4% | — | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
| LTM Sep 2026 | $133.6M | +39.6% | -6.2% | — | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
| Peer median (excluding IDYA) | $143.04M | +15.1% | +13.2% | 270.1% | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.94M | 50.93M | 23.39M | 7M | 218.71M |
| Cost of Revenue | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Gross Profit | 26.22M | 48.83M | 19.38M | 3.17M | 214.12M |
| Gross Margin | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| Research & Development | 58.16M | 89.54M | 129.51M | 294.67M | 314.7M |
| Selling, General & Admin | 18.33M | 21.8M | 24.3M | 35.47M | 63.32M |
| Operating Expenses | 76.48M | 111.33M | 153.81M | 330.14M | 373.43M |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| EBITDA | (48.04M) | (56.55M) | (108.95M) | (270.64M) | (109.11M) |
| EBITDA Margin | -171.9% | -111.0% | -465.9% | -3866.3% | -49.9% |
| Operating Income | (50.27M) | (62.5M) | (134.43M) | (326.98M) | (159.31M) |
| Operating Margin | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Interest Income | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 506K | 3.85M | 21.47M | 52.5M | 45.62M |
| Income Before Tax | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Pre-Tax Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Net Margin | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (Basic) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| EPS (Diluted) | (1.41) | (1.42) | (1.96) | (3.36) | (1.28) |
| Weighted Avg Shares | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
| Weighted Avg Shares (Diluted) | 35.25M | 41.44M | 57.52M | 81.68M | 88.49M |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.